# The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori

> **NCT06004401** · NA · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 400 (estimated)

## Conditions studied

- The Eradication Rate of Helicobacter Pylori

## Interventions

- **DRUG:** Vonopazan +Amoxicillin
- **DRUG:** Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin
- **DRUG:** Vonopazan +Minocycline
- **DRUG:** Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin

## Key facts

- **NCT ID:** NCT06004401
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-20
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004401, "The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06004401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*